I hadn’t heard much in a
while about sarilumab, fully human monoclonal antibody (MAB) against IL-6R
alpha. So I have been very interested in presentations at the EULAR 2014
Meeting in Paris.
[OP0028]
M. Genovese and colleagues
presented: “EFFECTS OF SARILUMAB PLUS MTX ON CLINICAL, RADIOGRAPHIC, AND
FUNCTIONAL ENDPOINTS IN PATIENTS WITH MODERATE-TO-SEVERE RHEUMATOID ARTHRITIS: RESULTS
OF A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, INTERNATIONAL STUDY”.
N=1197!!! Conclusions: “In this phase 3 study, both sarilumab doses (150 mg and
200 mg q2w), in combination with MTX, demonstrated efficacy in pts with active
RA who had inadequate response to MTX. Both sarilumab doses met clinical,
radiographic, and functional endpoints. Clinical response was maintained
throughout the 52-wk study period. Infection SAEs and laboratory abnormalities
with sarilumab are consistent with IL-6 signaling blockade.” This looks much
better than the studies presented a year ago.
[THU0275]
S. Fiore and collegaegues
looled at: “IL-6 RECEPTOR (IL-6R) BLOCKADE WITH SARILUMAB REDUCED CIRCULATING
MARKERS RELATED TO
SYNOVIAL INFLAMMATION AND
STRUCTURAL DAMAGE IN PATIENTS WITH RHEUMATOID ARTHRITIS (RA) IN A PHASE 2 “.STUDY”
Conclusions: “Sarilumab treatment in patients with RA resulted in significant dose-dependent
reduction in MMP-generated neo-epitope biomarkers related to joint and tissue
turnover.”
I’m a bit more confident
in the future of sarilumab. At least it looks much better than a year ago. This
year I’d like to say: sarilumab get to the market! Hope it won’t take too long.
Links:
ACR 2012: http://rheumatologe.blogspot.de/2012/12/sarilumab-at-acr-2012-in-washington.html
EULAR 2012: http://rheumatologe.blogspot.de/2012/06/sarilumab-news-from-eular-2012.html
EULAR 2012: http://rheumatologe.blogspot.de/2012/06/sarilumab-news-from-eular-2012.html
No comments:
Post a Comment